Results 81 to 90 of about 830,895 (193)

Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2

, 2012
Chemotherapy modestly prolongs survival of patients with advanced gastric cancer, but strategies are needed to increase its efficacy. Histone deacetylase (HDAC) inhibitors modify chromatin and can block cancer cell proliferation and promote ...
Herrmann, Ken, Zimmermann, Wolfgang, Hofheinz, Ralf, Friedrich, Teresa, Röcken, Christoph, Regel, Ivonne, Burgermeister, Elke, Ebert, Matthias P, Einwächter, Henrik, Merkl, Lisa, Schmid, Roland, Langer, Rupert, Regel, I;Merkl, L;Friedrich, T;Burgermeister, E;Zimmermann, W;Einwächter, H;Herrmann, K;Langer, R;Röcken, C;Hofheinz, R;Schmid, R;Ebert, MP   +12 more
core   +1 more source

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma

, 2011
BACKGROUND: We examine the potential value of a series of clinically relevant PI3K-mTOR inhibitors alone, or in combination with histone deacetylase inhibitors, in a model of head and neck squamous cell carcinoma (HNSCC)
D Rickwood, L Endo-Munoz, S Cameron, Endo-Munoz, L., de Long, L. M., A Dahler, L M de Long, Kherrouche, Z., Z Kherrouche, Guminski, A., Dahler, A., Cameron, S., Woolley, K., Saunders, N. A., Erlich, R. B., M Hazar-Rethinam, N A Saunders, A Guminski, Hazar-Rethinam, M., R B Erlich, K Wooley, Rickwood, D.   +21 more
core   +1 more source

Therapeutic applications of histone deacetylase inhibitors in sarcoma

, 2017
•Sarcomas are a diverse group of difficult-to-treat malignant tumors.•Histone deacetylase inhibitors are epigenetic drugs that can inhibit sarcoma growth in vitro and in vivo.•Histone deacetylase inhibitors can increase treatment efficiency when combined
Francis Hornicek, Tang, Fan, Tu, Chongqi, Hornicek, Francis, Chongqi Tu, Choy, Edwin, Edwin Choy, Zhenfeng Duan, Fan Tang, Duan, Zhenfeng   +9 more
core   +1 more source

Supplementary Data Figure 1 from The Effects of Histone Deacetylase Inhibitors on the Induction of Differentiation in Chondrosarcoma Cells

, 2007
Supplementary Data Figure 1 from The Effects of Histone Deacetylase Inhibitors on the Induction of Differentiation in Chondrosarcoma ...
Syunsaku Yamamoto (14979253), Tomoyuki Nakamura (2912780), Riku Sakimura (7328573), Tomoya Matsunobu (4054051), Xu Li (23864), Takamitsu Okada (14879195), Yang Li (7082), Yukihide Iwamoto (89775), Kazuhiro Tanaka (434060), Masuo Hanada (14879192)   +9 more
core   +1 more source

CCR Translation for This Article from Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma

, 2012
CCR Translation for This Article from Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal ...
Olga A. Agapova (14984954), Solange Landreville (14984951), Katie A. Matatall (14984957), Zachary T. Kneass (14984960), Michael D. Onken (14872359), Ryan S. Lee (14984963), Anne M. Bowcock (8648595), J. William Harbour (14872365)   +7 more
core   +1 more source

Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review

Frontiers in Oncology
Acute lymphocytic leukemia is a hematological malignancy that primarily affects children. Long-term chemotherapy is effective, but always causes different toxic side effects.
Yingjun Zhang, Yingjun Zhang, Ge Zhang, Ge Zhang, Yuefang Wang, Yuefang Wang, Lei Ye, Lei Ye, Luyun Peng, Luyun Peng, Rui Shi, Rui Shi, Siqi Guo, Siqi Guo, Jiajing He, Jiajing He, Hao Yang, Hao Yang, Qingkai Dai, Qingkai Dai   +19 more
doaj   +1 more source

The role of histone deacetylase inhibitors in uveal melanoma: Current evidence

, 2018
Uveal melanoma is the most common intraocular malignancy in adults, representing approximately 3% of all melanoma cases. Despite progress in chemotherapy, radiation and surgical treatment options, the prognosis and survival rates remain poor. Acetylation
Androudi, S., Garmpis, N., Damaskos, C., Tsatsos, M., Moschos M.M., Dettoraki M., Androudi S., Kalogeropoulos D., Lavaris A., Garmpis N., Damaskos C., Garmpi A., Tsatsos M., Kalogeropoulos, D., Moschos, M.M., Garmpi, A., Dettoraki, M., Lavaris, A.   +9 more
core   +1 more source

The Role of HDACs as Leukemia Therapy Targets using HDI

International Journal of Hematology-Oncology and Stem Cell Research, 2016
Histone deacetylases (HDACs) are the enzymes causing deacetylation of histone and non-histone substrates. Histone deacetylase inhibitors (HDIs) are a family of drugs eliminating the effect of HDACs in malignant cells via inhibition of HDACs.
Ahmad Ahmadzadeh, Elahe Khodadi, Mohammad Shahjahani, Jessika Bertacchini, Tina Vosoughi, Najmaldin Saki   +5 more
doaj  

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma

, 2016
Nidhi Tandon, Vijay Ramakrishnan, Shaji K Kumar Division of Hematology, Mayo Clinic, Rochester, MN, USA Abstract: The incorporation of various novel therapies has resulted in a significant survival benefit in newly diagnosed and relapsed patients with ...
Kumar SK, Tandon N, Ramakrishnan V
core  

Mapping the Safety Profile of Histone Deacetylase Inhibitors in Children with Cancer. [PDF]

Clin Epigenetics
Cianflone A, Fabozzi F, Cacace F, Rossitti E, Nappo S, Cillo F, Scarpa A, Mirabelli P, Tambaro FP.   +8 more
europepmc   +1 more source